Quick Answer
ORAMED PHARMACEUTICALS INC. reported Operating Income Loss of -$15.09 million for the year ending 2025.
- ORAMED PHARMACEUTICALS INC. showed a decrease of -18.1% in Operating Income Loss from 2024 to 2025.
- This data is from ORAMED PHARMACEUTICALS INC.'s annual report (Form 10-K), filed with the SEC on March 26, 2026.
- XBRL data for this metric is available from 2011 to 2025 (15 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Quarterly values from 10-Q filings: Q4 2010: -$601.6 thousand | Q1 2011: -$647.2 thousand | Q2 2011: -$591.5 thousand | Q4 2011: -$465.9 thousand | Q1 2012: -$940.4 thousand | Q2 2012: -$540.4 thousand | Q4 2012: -$731.8 thousand | Q1 2013: -$1.26 million | Q2 2013: -$1.33 million | Q4 2013: -$1.17 million | Q1 2014: -$1.19 million | Q2 2014: $1.90 million | Q4 2014: -$1.90 million | Q1 2015: -$1.67 million | Q2 2015: -$1.63 million | Q4 2015: $2.45 million | Q1 2016: -$1.91 million | Q2 2016: $2.11 million | Q4 2016: -$2.40 million | Q1 2017: -$3.37 million | Q2 2017: -$2.16 million | Q4 2017: -$2.73 million | Q1 2018: -$3.11 million | Q2 2018: -$4.53 million | Q4 2018: -$4.64 million | Q1 2019: -$3.57 million | Q2 2019: -$4.08 million | Q4 2019: -$2.43 million | Q1 2020: -$4.04 million | Q2 2020: -$2.27 million | Q4 2020: -$5.83 million | Q1 2021: -$4.87 million | Q1 2021: -$6.60 million | Q2 2021: -$6.12 million | Q2 2021: -$4.45 million | Q3 2021: -$7.49 million | Q4 2021: -$8.06 million | Q1 2022: -$11.25 million | Q2 2022: -$11.42 million | Q3 2022: -$8.19 million | Q4 2022: -$12.33 million | Q1 2023: -$5.21 million | Q2 2023: -$3.79 million | Q3 2023: -$2.89 million | Q1 2024: -$2.96 million | Q2 2024: -$3.14 million | Q3 2024: -$3.09 million | Q1 2025: -$4.50 million | Q2 2025: -$2.49 million | Q3 2025: -$2.43 million.
- Over the full 15 years of available data (2011 to 2025), ORAMED PHARMACEUTICALS INC.'s Operating Income Loss has declined by 519.6%.
- Historical annual values: Fiscal year 2025: -$15.09 million | Fiscal year 2024: -$12.78 million | Fiscal year 2023: -$15.77 million | Fiscal year 2022: -$40.60 million | Fiscal year 2021: -$24.22 million | Fiscal year 2020: -$11.76 million | Fiscal year 2019: -$14.63 million | Fiscal year 2018: -$13.53 million | Fiscal year 2017: -$10.77 million | Fiscal year 2016: -$10.01 million | Fiscal year 2015: -$7.38 million | Fiscal year 2014: -$5.91 million | Fiscal year 2013: $4.30 million | Fiscal year 2012: -$2.88 million | Fiscal year 2011: -$2.44 million.
- Data sourced from SEC EDGAR public filings as of August 5, 2026.
Last verified: